OakChart

Alector Inc

ALECHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 6:28 AM ET

2.54+0.09 (3.63%)
2026-11-13 13:06 CET
Market cap
$378.07M
Revenue, TTM
173.47 USD m
Net income, TTM
41.41 USD m
Free cash flow, TTM
-150.02 USD m
EPS diluted, TTM
0.36
Price / earnings
7.06
Compare

Price

ALEC against its 20, 50 and 200-day averages
Terms2050200Beat
Patternshover a marker to name it
RS 14Sales 67.8Price2.331.502.002.5045.0M90.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26ALECclose 2.5420-day 2.1850-day 2.07200-day 2.052.5452w high 2.8452-week range, not 6 months

10.6% under the 52-week high of 2.84 on 11 Nov 2026. 52-week low 1.09 on 3 Dec 2025. Last 15 sessions, 58.7% high to low

Volume 0.03× normal · the line is the 50-bar volume average

Setup. RS line 14
CANSLIM 5 of 6 — fails: 52-Week High/Low: 0-10% below High
VCP 4 of 6 — fails: 52-Week High/Low: 0-10% below High; RSI (14): Not Overbought (<60)
Minervini 3 of 4 — fails: 52-Week High/Low: 0-10% below High
Zanger 3 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5
Leaders 4 of 5 — fails: 52-Week High/Low: 0-10% below High
Breakout 2 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2
Growth 3 of 4 — fails: EPS Growth Next Year: High (>25%)
Quality 4 of 5 — fails: Debt/Equity: Low (<0.1)
Value 2 of 4 — fails: P/B: Under 2; Debt/Equity: Low (<0.1)
Income 1 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%)
Small Cap 3 of 4 — fails: Float: Under 100M
Accumulation 3 of 4 — fails: Institutional Transactions: Over +10%
Relative Strength 3 of 3

Profile

ALEC
52-week range, 83% of the way up
1.092.84

Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.

IndexRUT
Employees103
IPOFeb 07, 2019
Beta0.60
ATR, 14d0.21
Rel volume0.03
Short float7.67%
Insider own26.53%
Inst own70.16%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap$378.07M
Enterprise Value260.37M
Income41.41M
Sales173.47M
Book / share1.04
Cash / share0.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees103
IPOFeb 07, 2019

Ratios

Price / earnings7.06
Forward price / earnings-
Price / earnings / growth-
Price / sales2.18
Price / book2.45
Price / cash2.73
Price / free cash flow-
Value / cash profit5.09
Value / sales1.50
Quick Ratio4.10
Current Ratio4.10
Debt / equity0.18
Long-term debt / equity0.10
Options and shortYes / Yes

Earnings

Earnings / share0.36
Earnings next year-0.78
Earnings next quarter0.20
Earnings this year141.29%
Earnings next year-235.88%
Earnings growth, 5 years21.83%
Past earnings growth4.96% 10.72%
Past sales growth-46.00% -0.05%
Earnings vs last year133.60%
Sales vs last year151.23%
Earnings vs last quarter429.65%
Sales vs last quarter4895.89%
EarningsNov 05 AMC
Surprise591.37% 6743.11%

Ownership

Insiders own26.53%
Insider trades-0.57%
Institutions own70.16%
Institution trades2.03%
Return on assets16.53%
Return on equity47.52%
Return on capital32.28%
Gross Margin95.17%
Operating margin24.65%
Profit Margin23.87%
20-day average16.63%
50-day average22.68%
200-day average23.66%

Technical

Shares out112.27M
Shares floating109.39M
Short / float7.67%
Short ratio2.54
Short interest8.39M
52-week high2.84 -10.6%
52-week low1.09 +132.9%
Volatility11.33% 10.24%
Average range0.21
Strength index62.00
Market sensitivity0.60
Relative volume0.03
Avg Volume3.31M
Volume4,953

Performance

Perf Week10.90%
Perf Month32.96%
Perf Quarter23.88%
Perf Half Y17.57%
Perf YTD62.79%
Perf Year111.62%
Perf 3Y-32.64%
Perf 5Y-89.04%
Perf 10Y-
Recommendation2.57
Target Price3.90
Prev Close2.45
Price2.54
Change %3.65%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
TodayInitiatedWells FargoOverweight$7+175.6%
Apr 15, 2026UpgradeCantor FitzgeraldNeutral → Overweight
Mar 10, 2026UpgradeBTIG ResearchNeutral → Buy$6+136.3%
Oct 22, 2025DowngradeWilliam BlairOutperform → Mkt Perform
Oct 22, 2025DowngradeTD CowenBuy → Hold
Oct 22, 2025DowngradeMizuhoOutperform → Neutral$1.50-40.9%
Oct 22, 2025DowngradeCantor FitzgeraldOverweight → Neutral
Oct 22, 2025DowngradeBTIG ResearchBuy → Neutral
Jul 28, 2025UpgradeMizuhoNeutral → Outperform$3.50+37.8%
Dec 17, 2024DowngradeMizuhoOutperform → Neutral$9 → $2.50-1.6%

Peers

Mkt cap
TickerCompanyMkt cap
DNLIDenali Therapeutics Inc3.03B
VYGRVoyager Therapeutics Inc106.41M
ACIUAC Immune SA217.80M
PRTAProthena Corp Plc421.05M
ANNXAnnexon Inc758.32M
PMNProMIS Neurosciences Inc31.48M
CGTXCognition Therapeutics Inc62.08M
INMBINmune Bio Inc34.68M
PASGPassage Bio Inc12.90M
BIIBBiogen Inc37.01B

Insider trading

latest 14 of 42
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Wong-Sarad GracePrincipal Accounting OfficerSep 03 '26Sale2.675,16513,767109,640Sep 04 05:45 PM
Wong-Sarad GracePrincipal Accounting OfficerSep 04 '26Sale2.513,6259,094106,015Sep 04 05:45 PM
Wong-Sarad GracePrincipal Accounting OfficerSep 02 '26Sale2.756561,804114,805Sep 04 05:45 PM
Berkley Neil LindsayCFO & Chief Business OfficerSep 03 '26Sale2.6629,25177,948350,649Sep 04 05:45 PM
Rosenthal ArnonChief Executive OfficerSep 03 '26Sale2.6672,606193,4732,294,600Sep 04 05:45 PM
GRACE WONG-SARADOfficerSep 04 '26Proposed Sale2.513,6259,094Sep 04 04:05 PM
GRACE WONG-SARADOfficerSep 02 '26Proposed Sale2.756561,804Sep 02 05:09 PM
Arnon RosenthalOfficerSep 02 '26Proposed Sale2.4079,702191,285Sep 01 08:00 PM
Neil L. BerkleyOfficerSep 02 '26Proposed Sale2.4032,10377,047Sep 01 08:00 PM
Grace Wong-SaradOfficerSep 02 '26Proposed Sale2.405,66213,589Sep 01 08:00 PM
Rosenthal ArnonChief Executive OfficerJun 02 '26Sale1.9787,216172,1912,367,206Jun 03 05:30 PM
Wong-Sarad GracePrincipal Accounting OfficerJun 02 '26Sale1.975,70911,27198,936Jun 03 05:30 PM
Wong-Sarad GracePrincipal Accounting OfficerJun 03 '26Sale1.883,4756,54395,461Jun 03 05:30 PM
Berkley Neil LindsayCFO & Chief Business OfficerJun 02 '26Sale1.9719,36038,221379,900Jun 03 05:30 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.86B
VTIVanguard Morningstar Total Stock Market ETFAUM: 696.31B
IWOiShares Russell 2000 Growth ETFAUM: 14.25B
VXFVanguard Extended Market Index ETFAUM: 30.79B
SCHASchwab U.S. Small-Cap ETFAUM: 22.44B
VTWOVanguard Russell 2000 Index ETFAUM: 16.90B
IWCiShares Micro-Cap ETFAUM: 1.23B
VHTVanguard Health Care ETFAUM: 21.54B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.68B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 112.81M

News

latest 14 of 200

Quarterly earnings

2026Q3 EPS 1.110 beat -0.226, from -0.340 a year earlier. Sales 162.87 beat 2.38, from 3.26 a year earlier
EPS
1.1100-0.6232024Q4 EPS -0.020 against -0.62324Q42025Q1 EPS -0.410 against -0.48425Q12025Q2 EPS -0.300 against -0.46125Q22025Q3 EPS -0.340 against -0.40825Q32025Q4 EPS -0.340 against -0.37425Q42026Q1 EPS -0.210 against -0.28826Q12026Q2 EPS -0.210 against -0.22926Q22026Q3 EPS 1.110 against -0.22626Q3
Sales, USD millions
162.8702024Q4 sales 54.24 against 19.7824Q42025Q1 sales 3.70 against 4.3825Q12025Q2 sales 7.87 against 2.8025Q22025Q3 sales 3.26 against 3.4925Q32025Q4 sales 6.24 against 1.9625Q42026Q1 sales 1.05 against 9.6726Q12026Q2 sales 3.32 against 1.7126Q22026Q3 sales 162.87 against 2.3826Q3

The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.

PeriodReportedEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mSurpriseYear-ago quarterAnalystsNext session
2026Q3ended 2026-09-302026-11-05 16:301.110-0.2261.110162.872.38EPS -591.4% · sales +6743.1%vs 2025Q3, year-ago quarter · EPS -426.5% · sales +4895.9%6Open +4.31% vs SPY +0.25%. Close +9.57% vs SPY +0.31%
2026Q2ended 2026-06-302026-08-06 16:30-0.210-0.229-0.2073.321.71EPS -8.1% · sales +93.8%vs 2025Q2, year-ago quarter · EPS -30.0% · sales -57.8%7 EPS · 5 salesOpen +0.55% vs SPY +0.32%. Close -2.73% vs SPY +0.61%
2026Q1ended 2026-03-312026-05-07 16:30-0.210-0.288-0.2071.059.67EPS -27.0% · sales -89.2%vs 2025Q1, year-ago quarter · EPS -48.8% · sales -71.7%8 EPS · 7 salesOpen -13.11% vs SPY +0.46%. Close -13.93% vs SPY +0.83%
2025Q4ended 2025-12-312026-02-25 16:30-0.340-0.374-0.3406.241.96EPS -9.1% · sales +218.6%vs 2024Q4, year-ago quarter · EPS +1600.0% · sales -88.5%8 EPS · 7 salesOpen -11.30% vs SPY +0.02%. Close +7.11% vs SPY -0.56%
2025Q3ended 2025-09-302025-11-06 16:30-0.340-0.408-0.3383.263.49EPS -16.6% · sales -6.5%vs 2024Q3, year-ago quarter · EPS -20.9% · sales -78.8%8 EPS · 6 salesOpen -2.31% vs SPY -0.36%. Close -1.54% vs SPY +0.10%
2025Q2ended 2025-06-302025-08-07 16:30-0.300-0.461-0.3047.872.80EPS -35.0% · sales +180.7%vs 2024Q2, year-ago quarter · EPS -25.0% · sales -47.8%7 EPS · 5 salesOpen +11.64% vs SPY +0.29%. Close +47.26% vs SPY +0.78%
2025Q1ended 2025-03-312025-05-08 16:30-0.410-0.484-0.4073.704.38EPS -15.3% · sales -15.5%vs 2024Q1, year-ago quarter · EPS +7.9% · sales -76.7%6 EPS · 4 salesOpen 0.00% vs SPY +0.25%. Close +12.50% vs SPY -0.13%
2024Q4ended 2024-12-312025-02-26 16:30-0.020-0.623-0.02154.2419.78EPS -96.8% · sales +174.2%vs 2023Q4, year-ago quarter · EPS -95.9% · sales +257.1%9 EPS · 8 salesOpen +9.30% vs SPY +0.39%. Close -3.49% vs SPY -1.60%
2024Q3ended 2024-09-302024-11-06 16:30-0.430-0.534-0.43315.3415.70EPS -19.5% · sales -2.3%vs 2023Q3, year-ago quarter · EPS -18.9% · sales +68.6%11 EPS · 8 salesOpen +0.38% vs SPY +0.35%. Close +7.63% vs SPY +0.77%
2024Q2ended 2024-06-302024-08-07 16:30-0.400-0.501-0.40015.0814.36EPS -20.2% · sales +5.0%vs 2023Q2, year-ago quarter · EPS -2100.0% · sales -73.2%10 EPS · 8 salesOpen +12.02% vs SPY +1.01%. Close +3.87% vs SPY +2.31%
2024Q1ended 2024-03-312024-05-08 16:30-0.380-0.508-0.38515.8914.86EPS -25.2% · sales +7.0%vs 2023Q1, year-ago quarter · EPS -30.9% · sales -4.0%9 EPS · 7 salesOpen +0.77% vs SPY +0.04%. Close +0.19% vs SPY +0.58%
2023Q4ended 2023-12-312024-02-27 16:30-0.490-0.771-0.49115.198.84EPS -36.4% · sales +71.9%vs 2022Q4, year-ago quarter · EPS -22.2% · sales +5.2%12 EPS · 10 salesOpen -0.14% vs SPY -0.32%. Close -0.29% vs SPY -0.13%
2023Q3ended 2023-09-302023-11-07 16:30-0.530-0.657-0.5309.109.97EPS -19.4% · sales -8.7%vs 2022Q3, year-ago quarter · EPS -5.4% · sales -38.7%11 EPS · 9 sales-
2023Q2ended 2023-06-302023-08-03 16:300.020-0.8140.01656.214.18EPS -102.5% · sales +1243.8%vs 2022Q2, year-ago quarter · EPS -83.3% · sales -29.6%9 EPS · 6 sales-
2023Q1ended 2023-03-312023-05-04 16:30-0.550-0.759-0.55216.557.71EPS -27.5% · sales +114.6%vs 2022Q1, year-ago quarter · EPS +1.9% · sales -32.4%11 EPS · 7 sales-
2022Q4ended 2022-12-312023-02-28 16:30-0.630-0.464-0.63414.4430.15EPS +35.9% · sales -52.1%vs 2021Q4, year-ago quarter · EPS -7.4% · sales +3.2%11 EPS · 8 sales-

Annual earnings

2025FY EPS -1.390 beat -1.395, from -1.230 a year earlier. Sales 21.05 beat 16.92, from 100.56 a year earlier
EPS
0.0970-4.6202018FY EPS -4.620 against -1.02520182019FY EPS -1.710 against -1.64320192020FY EPS -2.450 against -2.43420202021FY EPS -0.450 against 0.09720212022FY EPS -1.620 against -1.38920222023FY EPS -1.560 against -1.83320232024FY EPS -1.230 against -1.77420242025FY EPS -1.390 against -1.3952025
Sales, USD millions
243.7502018FY sales 27.68 against 22.4320182019FY sales 21.22 against 21.6320192020FY sales 21.10 against 24.1520202021FY sales 207.09 against 243.7520212022FY sales 133.62 against 150.8420222023FY sales 97.06 against 91.1620232024FY sales 100.56 against 65.6620242025FY sales 21.05 against 16.922025

Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.

earnings feed, not the snapshot. Not the statement ratio.

PeriodEPS adjustedEPS estEPS reportedSales act, USD mSales est, USD mP/E, earnings feed
2030FYestimate--0.610--11.67-
2029FYestimate--0.713--1.67-
2028FYestimate--0.664--9.00-
2027FYestimate--0.780--14.30-
2026FYestimate-0.574--186.474.42
2025FY-1.390-1.395-1.39021.0516.92-
2024FY-1.230-1.774-1.233100.5665.66-
2023FY-1.560-1.833-1.55797.0691.16-
2022FY-1.620-1.389-1.617133.62150.84-
2021FY-0.4500.097-0.452207.09243.75213.99
2020FY-2.450-2.434-2.44621.1024.15-
2019FY-1.710-1.643-1.70721.2221.63-
2018FY-4.620-1.025-0.74927.6822.43-

Quarterly results

2026Q3 revenue 162.87, from 3.26 a year earlier. Operating margin 76.0%, from -1,157% a year earlier
Revenue, USD millions
162.8702024Q4 revenue 54.2424Q42025Q1 revenue 3.6725Q12025Q2 revenue 7.8725Q22025Q3 revenue 3.2625Q32025Q4 revenue 6.2425Q42026Q1 revenue 1.0526Q12026Q2 revenue 3.3226Q22026Q3 revenue 162.8726Q3
Operating margin
76.00-2,4022024Q4 operating margin -9.3%24Q42025Q1 operating margin -1,155%25Q12025Q2 operating margin -433.8%25Q22025Q3 operating margin -1,157%25Q32025Q4 operating margin -505.93%25Q42026Q1 operating margin -2,402%26Q12026Q2 operating margin -731.63%26Q22026Q3 operating margin 76.0%26Q3

From the quarterly statement. Not an estimate.

Estimate revisions

Latest snapshot of each period and type. 2026FY E 0.48 per share.
PeriodTypeScaleDateMeanvs prior date
2026FYEper share2026-11-060.48-224.4%
2026Q4Eper share2026-11-060.16-27.7%
2026FYRper share2026-11-060.51-194.4%
2026Q4Rper share2026-11-060.09+25.7%
2026Q4Sper share2026-11-0667.84-12.8%
2026FYS-2026-11-06174.93+164.4%
2026Q3Eper share2026-10-28-0.22-1.9%
2026Q3Rper share2026-10-28-0.22-0.4%
2026Q3Sper share2026-10-282.38+8.6%
2026Q2Eper share2026-08-06-0.23+3.3%
2026Q2Sper share2026-08-061.71+20.0%
2026Q2Rper share2026-07-30-0.22-2.2%
2026Q1Eper share2026-05-01-0.29+1.8%
2026Q1Rper share2026-04-30-0.24+0.8%
2026Q1Sper share2026-03-069.67-5.2%
2025FYEper share2026-02-18-1.40-2.6%
2025Q4Eper share2026-02-18-0.37-2.4%
2025FYRper share2026-02-18-1.42+0.0%
2025Q4Rper share2026-02-18-0.38+0.3%
2025Q4Sper share2026-02-181.96-8.5%
2025FYSper share2026-01-3116.920.0%
2025Q3Eper share2025-11-01-0.410.0%
2025Q3Rper share2025-10-28-0.41+0.3%
2025Q3Sper share2025-10-283.49+0.1%
2025Q2Eper share2025-07-26-0.460.0%
2025Q2Rper share2025-07-26-0.470.0%
2025Q2Sper share2025-07-262.800.0%
2025Q1Eper share2025-03-21-0.48+0.2%
2025Q1Rper share2025-02-27-0.51-3.2%
2025Q1Sper share2025-02-274.38-52.8%
2024FYEper share2025-02-26-1.770.0%
2024Q4Eper share2025-02-26-0.620.0%
2024FYRper share2025-02-26-1.770.0%
2024Q4Rper share2025-02-26-0.600.0%
2024FYSper share2025-02-2665.660.0%
2024Q4Sper share2025-02-2619.780.0%
2024Q3Eper share2024-10-26-0.530.0%
2024Q3Rper share2024-10-26-0.540.0%
2024Q3Sper share2024-10-2215.700.0%
2024Q2Eper share2024-07-26-0.50+0.1%
2024Q2Rper share2024-07-24-0.510.0%
2024Q2Sper share2024-07-2414.360.0%
2024Q1Sper share2024-04-2614.86+0.3%
2024Q1Rper share2024-04-12-0.570.0%
2024Q1Eper share2024-04-04-0.51+2.7%
2023FYRper share2024-02-22-1.82+0.0%
2023FYEper share2024-02-14-1.83+0.4%
2023FYSper share2024-01-2991.160.0%

Estimate history

Annual
Metric201720182019202020212022202320242025TTMMRQ
EPS per share-0.466-0.749-1.707-2.446-0.452-1.617-1.557-1.233-1.3880.3596-
Sales USD millions42821212071349710121173-
Shares million shares7070697982838599110-112
Quarterly
MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
EPS per share-0.433-0.021-0.407-0.304-0.338-0.34-0.207-0.2071.114
Sales USD millions1554483613163
Shares million shares9899100101107110111112112

Income statement, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Total Revenue173.4721.05-79.1%100.56+3.6%97.06-27.4%133.62-35.5%207.09+881.5%21.10-0.6%21.22-23.3%27.68
Cost of Goods Sold Incl. D&A8.389.66+9.3%8.84-0.1%8.85+4.5%8.47----
Gross Profit165.0911.38-87.6%91.72+4.0%88.21-29.5%125.14----
Selling, General and Administrative Excl. Other122.33157.19-33.0%234.51-2.3%239.95-8.8%262.98+11.4%236.13+13.1%208.77+62.0%128.89+53.5%83.95
Research and Development91.44113.40-36.0%177.10-3.4%183.27-12.9%210.42+11.1%189.41+20.7%156.87+56.0%100.53+37.7%73.03
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income42.76-145.81-142.79-151.74-137.83-37.36-194.94-113.25-57.29
Interest Expense---0.000.000.000.000.000.00
Unusual Expense7.8010.20+361.5%2.210.00--0.24-79.3%1.16-
Net Income Before Taxes41.77-142.76-118.92-125.18-130.06-36.33-190.23-105.39-52.25
Income Taxes0.360.17+30.8%0.13-97.5%5.21+60.3%3.250.000.000.000.00
Consolidated Net Income41.41-142.93-119.05-130.39-133.31-36.33-190.23-105.39-52.25
Net Income From Continuing Operations41.41-142.93-119.05-130.39-133.31-36.33-190.23-105.39-52.25
Net Income41.41-142.93-119.05-130.39-133.31-36.33-190.23-105.39-52.25
EPS (Recurring) per share0.42-1.32-1.22-1.56-1.62-0.45-2.44-1.69-0.75
EPS (Basic, Before Extraordinaries) per share0.36-1.39-1.23-1.56-1.62-0.45-2.45-1.71-0.75
EPS (Diluted) per share0.36-1.39-1.23-1.56-1.62-0.45-2.45-1.71-0.75
EBITDA51.14-136.15-133.95-142.89-129.36-29.05-187.67-107.67-56.27
Non-Operating Income (Expense)6.8113.25-49.2%26.08-1.8%26.56+241.4%7.78+655.3%1.03-79.2%4.95-45.1%9.02+79.0%5.04
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.7621.06-32.5%31.18-7.8%33.81-7.3%36.46-10.6%40.78+33.6%30.52+87.5%16.28+135.3%6.92
Price To Earnings Ratio ratio statement ratio, not the snapshot6.816.81-------
Price To Sales Ratio ratio1.197.631.826.885.708.0255.7650.13-
Gross Margin %95.1754.0991.2190.8893.66----
Operating Margin %24.65-692.83-142.00-156.33-103.16-18.04-923.95-533.70-206.99
Net Margin %23.87-679.16-118.39-134.34-99.77-17.54-901.64-496.65-188.78
Shares Outstanding million shares112.27110.36+11.4%99.09+16.7%84.88+2.4%82.90+1.1%81.99+3.4%79.32+14.9%69.05-1.0%69.75
Market Capitalization364.75364.75+97.1%185.09-72.4%671.41-12.0%763.33-54.5%1,678.35+40.0%1,198.94+1.0%1,187.56+2.1%1,162.75

Income statement, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Total Revenue162.87+4896.0%3.32-57.8%1.05-71.4%6.24-88.5%3.26-78.7%7.87-47.8%3.67-76.9%54.24+257.1%
Cost of Goods Sold Incl. D&A1.98-15.0%2.05-36.3%2.08+12.4%2.26+8.7%2.33+6.4%3.22+41.2%1.85-19.2%2.08-8.0%
Gross Profit160.88+17198.9%1.27-72.7%-1.04-156.8%3.98-92.4%0.93-92.9%4.65-63.7%1.83-86.5%52.16+303.4%
Selling, General and Administrative Excl. Other37.04-4.1%25.56-34.1%24.18-45.3%35.54-37.9%38.64-37.3%38.79-33.6%44.22-22.8%57.21-5.3%
Research and Development28.05+3.8%17.41-28.6%15.77-50.4%30.20-32.0%27.02-41.0%24.39-44.6%31.79-25.9%44.38-2.4%
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income123.84-24.29-25.22-31.57-37.71-34.14-42.40-5.04
Unusual Expense0.000.10-0.30-113.0%8.00+262.0%-0.100.002.302.21
Net Income Before Taxes124.66-22.86-22.93-37.10-34.67-30.52-40.47-2.03
Income Taxes0.060.130.000.17+240.0%0.000.00-100.0%0.00-100.0%0.05-97.0%
Consolidated Net Income124.60-22.99-22.93-37.27-34.67-30.52-40.47-2.07
Net Income From Continuing Operations124.60-22.99-22.93-37.27-34.67-30.52-40.47-2.07
Net Income124.60-22.99-22.93-37.27-34.67-30.52-40.47-2.07
EPS (Recurring) per share1.11-0.21-0.21-0.29-0.34-0.30-0.39-0.01
EPS (Basic, Before Extraordinaries) per share1.11-0.21-0.21-0.34-0.34-0.30-0.41-0.02
EPS (Diluted) per share1.11-0.21-0.21-0.34-0.34-0.30-0.41-0.02
EBITDA125.82-22.24-23.14-29.31-35.38-30.92-40.55-2.97
Non-Operating Income (Expense)0.82-72.1%1.53-57.6%1.99-52.8%2.47-52.7%2.94-52.7%3.61-48.4%4.22-44.8%5.22-32.0%
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.58-68.8%2.06-63.1%2.30-65.2%3.83-52.5%5.06-44.0%5.58-28.7%6.60-18.9%8.07-11.5%
Price To Earnings Ratio ratio statement ratio, not the snapshot6.81-------
Price To Sales Ratio ratio1.1916.1312.918.124.401.731.381.85
Gross Margin %98.7838.28-99.2463.7828.4759.0849.7096.17
Operating Margin %76.04-731.72-2,410.99-506.11-1,156.69-433.55-1,153.92-9.30
Net Margin %76.50-692.47-2,192.16-597.51-1,063.40-387.66-1,101.55-3.82
Shares Outstanding million shares112.27+4.5%111.66+10.3%111.03+11.0%110.36+11.4%107.45+9.7%101.21+4.0%99.99+3.7%99.09+16.7%
Market Capitalization364.75+21.7%223.16+59.4%237.28+94.7%170.28-8.0%299.59-33.9%139.99-68.0%121.88-78.9%185.09-72.4%

Balance sheet, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/20182017FY12/31/2017
Cash & Short Term Investments256.02-38.1%413.40-24.7%548.86-23.0%712.85-3.0%735.25+77.9%413.31+17.1%353.07+21.6%290.41+794.9%32.45
Short Term Receivables0.000.000.00-100.0%2.59-65.0%7.390.000.000.00-100.0%200.24
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets10.43-8.7%11.42-32.6%16.95+54.1%11.00+55.6%7.07-13.8%8.20+88.1%4.36+57.4%2.77+889.3%0.28
Total Current Assets266.45-37.3%424.82-24.9%565.81-22.1%726.43-3.1%749.71+77.9%421.51+17.9%357.44+21.9%293.18+25.8%232.97
Net Property, Plant & Equipment24.55-33.8%37.10-21.2%47.06-11.8%53.33-7.9%57.90-7.6%62.65+0.5%62.33+469.7%10.94+286.6%2.83
Total Investments and Advances1.850.0%1.85+19.4%1.55+5.4%1.470.0%1.470.0%1.470.0%1.470.0%1.470.00
Intangible Assets---0.000.000.000.000.00-
Other Assets0.39-91.4%4.54-38.8%7.42+15.8%6.41+15.1%5.57+112.6%2.62+285.3%0.68-75.5%2.77+1008.0%0.25
Total Assets293.24-37.4%468.30-24.7%621.83-21.1%787.65-3.3%814.66+66.9%488.25+15.7%421.91+36.8%308.36+30.6%236.06
Short Term Debt Incl. Current Port. of LT Debt9.42+7.7%8.75+3.4%8.46+5.0%8.06+3.5%7.79+3.7%7.51+14.3%6.570.000.00
Accounts Payable1.69-23.5%2.21-41.4%3.77-10.0%4.19-11.8%4.75+58.3%3.00+971.4%0.28+115.4%0.13-88.6%1.14
Other Current Liabilities58.39-48.8%114.09-31.2%165.71+103.2%81.56-35.8%127.01+120.6%57.57+4.4%55.13+15.3%47.82+82.1%26.26
Total Current Liabilities69.50-44.4%125.06-29.7%177.95+89.7%93.81-32.8%139.56+105.0%68.09+9.9%61.97+29.2%47.95+75.0%27.40
Long Term Debt26.81-20.6%33.77+10.9%30.46-13.6%35.27-11.4%39.81-9.0%43.74+5.5%41.470.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities166.27-9.0%182.68-34.6%279.26-37.1%444.13+32.7%334.57+207.3%108.89-12.0%123.73-16.0%147.29-19.6%183.21
Total Liabilities262.59-23.1%341.50-30.0%487.67-14.9%573.21+11.5%513.93+132.8%220.72-2.8%227.17+16.4%195.24-7.3%210.61
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00-100.0%210.52+171.7%77.48
Common Equity30.65-75.8%126.80-5.5%134.16-37.4%214.44-28.7%300.72+12.4%267.53+37.4%194.74-97.40-52.03
Total Shareholders Equity30.65-75.8%126.80-5.5%134.16-37.4%214.44-28.7%300.72+12.4%267.53+37.4%194.74+72.2%113.12+344.5%25.45
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity30.65-75.8%126.80-5.5%134.16-37.4%214.44-28.7%300.72+12.4%267.53+37.4%194.74+72.2%113.12+344.5%25.45
Total Liabilities & Stockholders Equity293.24-37.4%468.30-24.7%621.83-21.1%787.65-3.3%814.66+66.9%488.25+15.7%421.91+36.8%308.36+30.6%236.06
Book Value Per Share per share0.28-78.1%1.28-19.0%1.58-39.0%2.59-29.4%3.67+8.9%3.37+19.5%2.82-1.40-0.75
Tangible Book Value Per Share per share0.28-78.1%1.28-19.0%1.58-39.0%2.59-29.4%3.67+8.9%3.37+19.5%2.82-1.40-0.75
Full-Time Employees people103-56.7%238-2.5%244-10.6%273+31.3%208+21.6%171+41.3%121+55.1%78-
Price to Book Ratio ratio2.361.564.133.025.634.496.115.32-
Return on Assets %-37.54-21.84-18.50-16.64-5.58-41.80-28.86-19.19-22.39
Return on Equity %-181.56-91.24-74.81-51.75-12.79-82.30-68.46-75.41-83.25
Return on Invested Capital %-248.75-74.14-79.21-53.39-10.67-61.11-44.61-46.19-127.61
Quick Ratio ratio3.833.403.187.745.376.195.776.118.50
Current Ratio ratio3.833.403.187.745.376.195.776.118.50

Cash flow, annual

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
MetricTTM2025FY12/31/20252024FY12/31/20242023FY12/31/20232022FY12/31/20222021FY12/31/20212020FY12/31/20202019FY12/31/20192018FY12/31/2018
Net Income41.41-142.93-119.05-130.39-133.31-36.33-190.23-105.39-52.25
Depreciation8.389.66+9.3%8.84-0.1%8.85+4.5%8.47+1.9%8.31+14.5%7.26+30.3%5.57+446.1%1.02
Other Funds (Non Cash)12.3323.29-14.7%27.29-0.9%27.53-38.8%44.98+4.9%42.88+36.3%31.45+146.1%12.78+195.2%4.33
Funds from Operations62.12-109.97-82.92-94.02-79.86-637.1%14.87-151.51-87.03-46.90
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-211.99-74.06-146.99-90.15-251.4%59.53-79.0%283.68-15.22-12.27-107.0%174.36
Cash from Operating Activities-149.88-184.03-229.91-184.16-20.33-106.8%298.55-166.73-99.31-177.9%127.46
Capital Expenditures-0.15-0.04-1.25-2.38-4.12-3.25-5.03-15.27-1.88
Net Assets From Acquisitions-0.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.300.000.000.000.000.000.000.00-
Purchase or Sale of Investments153.61196.64+81.4%108.39+3.9%104.30-154.90-46.42-100.02-33.61-222.24
Purchase of Investments-166.46-271.88-467.74-551.73-556.90-343.40-506.81-529.61-472.24
Sale Or Maturity of Investments320.06468.52-18.7%576.13-12.2%656.03+63.2%402.00+35.4%296.99-27.0%406.79-18.0%496.00+98.4%250.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities153.76196.60+83.5%107.13+5.1%101.92-159.01-49.66-105.05-48.87-224.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock5.3720.00-71.9%71.11+2688.6%2.55-43.5%4.51-85.1%30.30-86.9%232.11+34.7%172.35+31.4%131.15
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock5.3720.00-71.9%71.11+2688.6%2.55-43.5%4.51-85.1%30.30-86.9%232.11+34.7%172.35+31.4%131.15
Proceedsfrom Stock Options5.3619.98-71.9%71.11+4737.4%1.47+0.7%1.46-17.0%1.76-99.2%224.60+32.1%170.04+29.7%131.15
Issuance or Reduction of Debt, Net-10.430.00-100.0%9.390.000.000.000.000.000.00
Change in Long Term Debt-10.430.00-100.0%9.390.000.000.000.000.000.00
Issuance of Long Term Debt0.000.00-100.0%9.390.000.000.000.000.000.00
Reduction of Long Term Debt-10.430.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.140.22-78.8%1.040.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities-4.9120.21-75.2%81.54+3097.6%2.55-43.5%4.51-85.1%30.30-86.9%232.11+34.7%172.35+31.4%131.15
Net Change in Cash-1.0332.78-41.23-79.69-174.83-162.6%279.18-39.67-264.1%24.17-29.9%34.49
Free Cash Flow-150.02-184.07-231.16-186.54-24.45-108.3%295.30-171.77-114.57-191.2%125.58
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow ratio-----5.62---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Cash & Short Term Investments138.70-52.4%172.80-43.8%206.51-41.8%256.02-38.1%291.11-36.3%307.28-39.0%354.55-36.9%413.40-24.7%
Short Term Receivables0.000.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.000.00
Other Current Assets6.65-28.3%7.29-38.7%8.57-29.2%10.43-8.7%9.28-23.7%11.90-27.3%12.10-37.3%11.42-32.6%
Total Current Assets145.35-51.6%180.09-43.6%215.08-41.3%266.45-37.3%300.38-36.0%319.18-38.6%366.65-36.9%424.82-24.9%
Net Property, Plant & Equipment18.29-36.0%20.57-33.4%22.62-35.9%24.55-33.8%28.58-26.8%30.90-28.8%35.29-21.9%37.10-21.2%
Total Investments and Advances1.850.0%1.850.0%1.850.0%1.850.0%1.85+19.4%1.85+19.4%1.85+19.4%1.85+19.4%
Other Assets0.30-93.3%0.35-92.2%0.37-91.8%0.39-91.4%4.47-26.6%4.49-26.6%4.52-38.9%4.54-38.8%
Total Assets165.78-50.6%202.85-43.1%239.92-41.2%293.24-37.4%335.29-35.0%356.42-37.6%408.30-35.8%468.30-24.7%
Short Term Debt Incl. Current Port. of LT Debt9.29+3.5%19.06+114.2%10.62+20.3%9.42+7.7%8.98+3.5%8.90+3.4%8.83+3.4%8.75+3.4%
Accounts Payable1.14-76.1%2.28+2.7%1.42-39.1%1.69-23.5%4.76-5.2%2.22-49.3%2.33-49.2%2.21-41.4%
Other Current Liabilities24.98-62.3%12.89-82.4%28.93-70.7%58.39-48.8%66.23-48.6%73.23-45.6%98.62-35.0%114.09-31.2%
Total Current Liabilities35.41-55.7%34.24-59.4%40.97-62.7%69.50-44.4%79.96-43.9%84.35-42.9%109.77-33.4%125.06-29.7%
Long Term Debt11.71-59.5%13.70-55.2%23.93-25.7%26.81-20.6%28.90+11.3%30.58+11.2%32.22+11.0%33.77+10.9%
Provision for Risks Charges0.000.000.000.000.000.000.000.00
Other Liabilities2.08-98.8%164.89-3.2%164.64-4.1%166.27-9.0%168.71-26.2%170.31-30.5%171.70-34.6%182.68-34.6%
Total Liabilities49.21-82.3%212.82-25.4%229.53-26.8%262.59-23.1%277.57-30.1%285.25-32.1%313.69-31.3%341.50-30.0%
Non-Equity Reserves0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.00
Common Equity116.57+102.0%-9.97-114.0%10.38-89.0%30.65-75.8%57.71-51.5%71.17-52.7%94.61-47.1%126.80-5.5%
Total Shareholders Equity116.57+102.0%-9.97-114.0%10.38-89.0%30.65-75.8%57.71-51.5%71.17-52.7%94.61-47.1%126.80-5.5%
Accumulated Minority Interest0.000.000.000.000.000.000.000.00
Total Equity116.57+102.0%-9.97-114.0%10.38-89.0%30.65-75.8%57.71-51.5%71.17-52.7%94.61-47.1%126.80-5.5%
Total Liabilities & Stockholders Equity165.78-50.6%202.85-43.1%239.92-41.2%293.24-37.4%335.29-35.0%356.42-37.6%408.30-35.8%468.30-24.7%
Book Value Per Share per share1.04+92.6%-0.09-112.9%0.09-90.5%0.28-78.1%0.54-55.4%0.70-54.8%0.95-48.9%1.28-19.0%
Tangible Book Value Per Share per share1.04+92.6%-0.09-112.9%0.09-90.5%0.28-78.1%0.54-55.4%0.70-54.8%0.95-48.9%1.28-19.0%
Full-Time Employees people---103-56.7%-163175238-2.5%
Price to Book Ratio ratio2.3621.507.742.904.211.480.961.56
Return on Assets %16.53-42.15-38.69-37.54-25.31-24.87-23.65-21.84
Return on Equity %47.52-385.11-238.85-181.56-121.98-103.98-90.26-91.24
Return on Invested Capital %97.13-616.52-66.82-64.86-40.03-30.00-31.91-1.29
Quick Ratio ratio4.105.265.253.833.763.783.343.40
Current Ratio ratio4.105.265.253.833.763.783.343.40

Cash flow, quarterly

USD millions, except where the row names a unit. The percent under a figure is against the same period a year earlier. TTM has no earlier TTM to compare with, and a ratio or a margin has no change.
Metric2026Q39/30/20262026Q26/30/20262026Q13/31/20262025Q412/31/20252025Q39/30/20252025Q26/30/20252025Q13/31/20252024Q412/31/2024
Net Income124.60-22.99-22.93-37.27-34.67-30.52-40.47-2.07
Depreciation1.98-15.0%2.05-36.3%2.08+12.4%2.26+8.7%2.33+6.4%3.22+41.2%1.85-19.2%2.08-8.0%
Other Funds (Non Cash)2.38-51.7%2.19-66.5%2.32-63.7%5.45-28.6%4.93-38.2%6.53+9.7%6.39+11.5%7.63+12.5%
Funds from Operations128.96-18.75-18.53-29.56-486.9%-27.41-20.78-32.237.64
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital-153.12-15.46-31.29-12.13-5.11-28.27-28.55-62.66
Cash from Operating Activities-24.15-34.22-49.81-41.69-32.51-49.05-60.78-55.03
Capital Expenditures0.00-0.03-0.120.00-0.01-0.01-0.02-0.17
Net Assets From Acquisitions-0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.300.000.000.000.000.000.000.00
Purchase or Sale of Investments49.79+0.5%17.15-69.2%61.07-7.1%25.60-38.4%49.55+22.2%55.73+48.7%65.7541.58+127.2%
Purchase of Investments-5.75-27.85-51.80-81.05-58.95-76.08-55.79-86.62
Sale Or Maturity of Investments55.54-48.8%45.00-65.9%112.87-7.1%106.65-16.8%108.50-12.4%131.82-5.0%121.55-34.4%128.20-17.6%
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities50.09+1.1%17.12-69.3%60.95-7.3%25.60-38.2%49.54+22.8%55.72+50.0%65.7341.40+129.1%
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.000.000.00
Change in Capital Stock0.05-99.7%0.000.035.3014.700.000.00-100.0%0.00-100.0%
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.05-99.7%0.000.035.3014.700.000.00-100.0%0.00-100.0%
Proceedsfrom Stock Options0.05-99.7%0.000.035.2814.700.000.00-100.0%0.00-100.0%
Issuance or Reduction of Debt, Net-10.430.000.000.00-100.0%0.000.000.009.39
Change in Long Term Debt-10.430.000.000.00-100.0%0.000.000.009.39
Issuance of Long Term Debt0.000.000.000.00-100.0%0.000.000.009.39
Reduction of Long Term Debt-10.430.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.05-58.3%0.000.10-75.0%0.000.12-81.3%0.000.40
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities-10.38-170.6%0.05-58.3%0.035.39-44.9%14.700.12-81.3%0.00-100.0%9.79+1559.3%
Net Change in Cash15.56-51.0%-17.05-350.7%11.16+125.5%-10.7031.736.804.95-3.84
Free Cash Flow-24.15-34.25-49.93-41.69-32.52-49.06-60.80-55.20

Revenue breakdown

USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.

Product
Name20242025vs 20242025 share
Biological Products, (No Diagnostic Substances)100.5621.05-79.1%100.0%
Total100.5621.05-79.1%100.0%
Region
Name20242025vs 20242025 share
United States100.5621.05-79.1%100.0%
Total100.5621.05-79.1%100.0%

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-307.67%8.4M109.4M3.29M
2026-10-159.41%10.3M108.9M2.96M
2026-09-307.46%6.1M82.4M1.15M
2026-09-157.41%6.1M82.4M1.19M
2026-08-317.51%6.2M82.1M997.59K
2026-08-147.19%5.9M82.1M904.18K
2026-07-317.22%5.6M78.2M706.99K
2026-07-157.29%5.7M77.7M721.97K
2026-06-307.35%5.7M77.8M757.73K
2026-06-156.75%5.2M77.8M644.09K
2026-05-296.55%5.1M77.7M692.03K
2026-05-156.19%4.9M78.5M696.02K
2026-04-306.65%5.0M75.2M769.11K
2026-04-156.89%5.2M74.7M817.40K
2026-03-318.44%6.3M74.5M885.91K
2026-03-138.07%6.0M74.5M990.05K
2026-02-278.06%6.0M74.5M1.15M
2026-02-138.28%6.1M73.7M1.25M
2026-01-308.55%6.5M76.4M1.47M
2026-01-158.49%6.5M76.4M2.73M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.501.452.451.460.0001.000.000.965-0.0180.000
call1.001.002.000.8813.0846.000.000.929-0.0190.000
call1.500.551.550.559.00520.000.000.881-0.0170.001
call2.000.150.800.554.2731,4942.000.795-0.0140.001
call2.500.000.300.292.2471140.000.553-0.0230.001
call5.000.000.250.043.2778.000.000.107-0.0140.001
call7.500.000.750.054.4982.000.000.086-0.0160.001
put0.500.001.000.008.0440.000.00-0.028-0.0110.000
put1.000.001.000.008.4150.000.00-0.082-0.0290.001
put1.500.001.000.053.00411.000.00-0.081-0.0110.001
put2.000.000.100.102.0721,0631.00-0.205-0.0130.001
put2.500.000.450.142.2614.000.00-0.442-0.0240.001
put5.002.203.200.007.5210.000.00-0.893-0.0130.001
put7.504.605.600.008.3420.000.00-0.914-0.0150.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-26SCHEDULE 13GSEC
2026-10-23SCHEDULE 13GSEC
2026-10-16424B5SEC
2026-10-168-KCurrent report2026-10-15SEC
2026-10-16FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-14SEC
2026-10-154Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-10-148-KCurrent report2026-10-13SEC
2026-10-058-KCurrent report2026-09-30SEC
2026-09-18SCHEDULE 13GSEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-214Statement of changes in beneficial ownership of securities2026-08-19SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-07-094Statement of changes in beneficial ownership of securities2026-07-09SEC
2026-07-088-KCurrent report2026-07-06SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-17SEC
2026-06-178-KCurrent report2026-06-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900296.09K5
2026-080000
2026-070000
2026-0600228.22K4
2026-050000
2026-04004.82K1
2026-0300263.58K5
2026-020010.20K1
2026-010000
2025-1200219.99K5
2025-110000

Institutional holders

Manager% owned
TCG Crossover Management, LLC9.01%
Nantahala Capital Management, LLC7.78%
BlackRock, Inc.7.07%
ACADIAN ASSET MANAGEMENT LLC4.00%
VANGUARD CAPITAL MANAGEMENT LLC3.61%
Kynam Capital Management, LP3.43%
Merck & Co., Inc.3.19%
BALYASNY ASSET MANAGEMENT L.P.2.92%
683 Capital Management, LLC2.88%
D. E. Shaw & Co., Inc.2.67%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.56%
iShares Russell 2000 ETF2.30%
Select Biotechnology Portfolio1.24%
Fidelity Small Cap Index Fund0.96%
VANGUARD EXTENDED MARKET INDEX FUND0.93%
iShares Russell 2000 Growth ETF0.74%
Avantis Emerging Markets Value ETF0.66%
VANGUARD EXPLORER FUND0.61%
BlackRock Advantage Small Cap Core Fund0.57%
VANGUARD STRATEGIC SMALL-CAP EQUITY FUND0.57%

OakChart. ALEC. Cached 15 minutes. Terms